HB Fuller stock hits 52-week low at $56.97 amid 27% annual drop

Published 26/02/2025, 19:36
HB Fuller stock hits 52-week low at $56.97 amid 27% annual drop

In a challenging market environment, HB Fuller (NYSE:FUL) Company’s stock has touched a 52-week low, dipping to $56.97. Despite market pressures, the company maintains a remarkable 55-year streak of consistent dividend payments, with 32 consecutive years of dividend increases. InvestingPro analysis shows the stock typically exhibits low price volatility. The adhesive manufacturing giant has faced a tough year, with its stock price reflecting a significant 1-year change, plummeting by 27.03%. With a market capitalization of $3.1 billion and EBITDA of $558 million, investors have been cautious as the company navigates through market headwinds, including supply chain disruptions and fluctuating raw material costs. The 52-week low serves as a critical marker for the company, which is now under pressure to demonstrate resilience and a strategic path forward to reassure shareholders and potentially attract value-seeking buyers. According to InvestingPro’s Fair Value analysis, the stock appears undervalued at current levels, with analysts maintaining a profitable outlook for the year ahead. Discover more insights and 6 additional ProTips with an InvestingPro subscription.

In other recent news, H.B. Fuller reported its Q4 2024 financial results, with earnings per share (EPS) of $0.92, missing the forecasted $1.23. The company’s revenue reached $923 million, falling short of the projected $945.32 million. Despite these results, H.B. Fuller continues to focus on strategic acquisitions and operational efficiencies, although market conditions remain challenging, particularly in Europe. The company announced the acquisitions of two medical adhesive companies, GEMSRL and MediPhil Limited, to enhance its market position in cyanoacrylates and expand its presence in the tissue adhesives market. H.B. Fuller also divested its flooring business as part of its portfolio management strategy. Analyst firms have noted these strategic moves, with some expressing cautious optimism about the company’s direction. The company expects a 2-4% decline in net revenue for FY 2025, with organic revenue forecasted to be flat to up 2%, and adjusted EBITDA guidance set between $600 million and $625 million. H.B. Fuller aims for a long-term EBITDA margin of over 20%, with ongoing efforts to manage costs and implement pricing initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.